Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

141
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
141
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

162
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
162
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

62
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
62
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

333
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
333
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

3.3K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.3K
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

5.5K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overview of methodology and characteristics of national acute coronary syndrome registries in high-income countries: a scoping review.

European heart journal open·2026
Same author

Hypertension and cardiometabolic multimorbidity: an analysis of 3.4 million participants from the global May Measurement Month blood pressure screening campaign.

BMJ public health·2026
Same author

Combined hepatorenal denervation for hypertension and cardiometabolic disease: a first-in-human study.

European heart journal·2026
Same author

Single Interventions (Pharmacological or Renal Denervation) Are Not Sufficient to Achieve Blood Pressure Control in Resistant Hypertension a Systematic Review and Meta-Analysis.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Renal denervation in 2026: trial evidence, guideline recommendations and implementation strategies for clinical practice.

Heart (British Cardiac Society)·2026
Same author

Body composition and muscle health changes after providing vascular imaging results in older adults: secondary analysis of a randomised controlled trial.

Aging clinical and experimental research·2026

Related Experiment Video

Updated: Oct 10, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Lipoprotein (a) and Hypertension.

Natalie C Ward1, Janis M Nolde1, Justine Chan1

  • 1Dobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia.

Current Hypertension Reports
|December 10, 2021
PubMed
Summary
This summary is machine-generated.

Elevated lipoprotein (a) is a risk factor for cardiovascular disease. In hypertensive patients, about 30% had high lipoprotein (a) levels, suggesting its importance in risk stratification.

Keywords:
AtherosclerosisCardiovascular riskDyslipidemiaHypertensionLipoprotein (a)Renal functionVascular function

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.6K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Related Experiment Videos

Last Updated: Oct 10, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.6K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Area of Science:

  • Cardiovascular Medicine
  • Lipidology
  • Hypertension Research

Background:

  • Elevated lipoprotein (a) is an independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease.
  • Limited data exist on the association between elevated lipoprotein (a) and hypertension.
  • Mechanistic links between lipoprotein (a) and hypertension, such as renal impairment or vascular effects, are not well-established.

Purpose of the Study:

  • To review associations between elevated blood pressure and lipoprotein (a).
  • To explore possible causal links between elevated lipoprotein (a) and hypertension.
  • To report the prevalence of elevated lipoprotein (a) in hypertensive patients.

Main Methods:

  • Literature review of studies on lipoprotein (a) and hypertension.
  • Analysis of clinical data from a hypertensive patient cohort.
  • Assessment of lipoprotein (a) levels in at-risk individuals.

Main Results:

  • Approximately 30% of patients in an at-risk, hypertensive cohort exhibited elevated lipoprotein (a) levels.
  • Limited evidence currently supports a direct association between elevated lipoprotein (a) and hypertension.
  • Further research is needed to elucidate mechanistic pathways linking lipoprotein (a) and hypertension.

Conclusions:

  • Elevated lipoprotein (a) may be a significant factor in hypertensive patients.
  • Measurement of lipoprotein (a) could aid in cardiovascular risk stratification for hypertensive individuals.
  • Further investigation into the relationship between lipoprotein (a) and hypertension is warranted.